Addressing the current challenges of non-small-cell lung cancer clinical trial accrual

Watter J. Curran, Joan H. Schiller, Allan C. Wolkin, Robert L. Comis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.

Original languageEnglish (US)
Pages (from-to)222-226
Number of pages5
JournalClinical Lung Cancer
Volume9
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Clinical Trials
Research Personnel
Industry
Communication
Delivery of Health Care
Physicians
Research
Neoplasms

Keywords

  • Cooperative group
  • Enrollment recommendations
  • Participation
  • Patient advocates
  • Study activation

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. / Curran, Watter J.; Schiller, Joan H.; Wolkin, Allan C.; Comis, Robert L.

In: Clinical Lung Cancer, Vol. 9, No. 4, 07.2008, p. 222-226.

Research output: Contribution to journalArticle

Curran, Watter J. ; Schiller, Joan H. ; Wolkin, Allan C. ; Comis, Robert L. / Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. In: Clinical Lung Cancer. 2008 ; Vol. 9, No. 4. pp. 222-226.
@article{062e321dbcf544308dea668b7a342c50,
title = "Addressing the current challenges of non-small-cell lung cancer clinical trial accrual",
abstract = "Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.",
keywords = "Cooperative group, Enrollment recommendations, Participation, Patient advocates, Study activation",
author = "Curran, {Watter J.} and Schiller, {Joan H.} and Wolkin, {Allan C.} and Comis, {Robert L.}",
year = "2008",
month = "7",
doi = "10.3816/CLC.2008.n.033",
language = "English (US)",
volume = "9",
pages = "222--226",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Addressing the current challenges of non-small-cell lung cancer clinical trial accrual

AU - Curran, Watter J.

AU - Schiller, Joan H.

AU - Wolkin, Allan C.

AU - Comis, Robert L.

PY - 2008/7

Y1 - 2008/7

N2 - Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.

AB - Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.

KW - Cooperative group

KW - Enrollment recommendations

KW - Participation

KW - Patient advocates

KW - Study activation

UR - http://www.scopus.com/inward/record.url?scp=49249095150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249095150&partnerID=8YFLogxK

U2 - 10.3816/CLC.2008.n.033

DO - 10.3816/CLC.2008.n.033

M3 - Article

C2 - 18650170

AN - SCOPUS:49249095150

VL - 9

SP - 222

EP - 226

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -